v3.19.3
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenue:        
Grant and licensing revenue $ 6,439 $ 1,840,009 $ 1,049,988 $ 3,735,713
Operating expenses:        
Research and development 3,129,356 4,403,759 9,725,744 10,756,485
General and administrative 1,993,136 1,585,600 7,201,196 4,727,105
Goodwill impairment loss 737,000 737,000
Change in fair value of contingent consideration 502,000 114,838 728,290 665,936
Total operating expenses 6,361,492 6,104,197 18,392,230 16,149,526
Loss from operations (6,355,053) (4,264,188) (17,342,242) (12,413,813)
Interest income 97,415 83,509 373,060 131,306
Other (expense) income, net (73,275) 31,704 (80,539) 153,500
Total non-operating income 24,140 115,213 292,521 284,806
Net loss before income taxes (6,330,913) (4,148,975) (17,049,721) (12,129,007)
Income tax benefit (expense) 225,389 (45,178) 665,080
Net loss (6,330,913) (3,923,586) (17,094,899) (11,463,927)
Net loss - non-controlling interest (136,315) (265,024) (413,955) (668,219)
Net loss attributable to Heat Biologics, Inc. $ (6,194,598) $ (3,658,562) $ (16,680,944) $ (10,795,708)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.18) $ (0.16) $ (0.50) $ (0.75)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted 33,650,829 23,143,952 33,255,535 14,359,429
Other comprehensive loss:        
Net loss $ (6,330,913) $ (3,923,586) $ (17,094,899) $ (11,463,927)
Unrealized gain on foreign currency translation 63,711 39,377 72,134 110,648
Total other comprehensive loss (6,267,202) (3,884,209) (17,022,765) (11,353,279)
Comprehensive loss attributable to non-controlling interest (136,315) (265,024) (413,955) (668,219)
Comprehensive loss $ (6,130,887) $ (3,619,185) $ (16,608,810) $ (10,685,060)

Source